FDA approves Johnson & Johnson diabetes drug, canagliflozin

By Toni Clarke (Reuters) – FDA has approved a new diabetes drug from Johnson & Johnson, making it the first in its class to be approved in the United States. The U.S. Food and Drug Administration approved the drug, Invokana, after data showed it was effective in lowering blood sugar in patients with Type 2 diabetes, the most common form of the disease. The FDA has asked for five postmarketing studies for the drug including a cardiovascular outcomes trial, an enhanced pharmacovigilance program, a bone safety study and two pediatric studies, the agency said in a statement on its website. …